Ribomic Expands Clinical Trial Sites for Achondroplasia Treatment to 10

TOKYO, Aug 03 (Pulse News Wire) – RIBOMIC Inc. (4591.T) announced today that it has expanded the number of clinical trial sites for umedaptanib pegol, an anti-FGF2 aptamer treatment for achondroplasia, to ten institutions across Japan.

The company received Institutional Review Board (IRB) approval at four additional sites, bringing the total number of participating medical facilities to ten. This Phase III clinical trial focuses on pediatric patients aged two to fourteen years old suffering from achondroplasia. Due to the rarity of the condition and the involvement of growing children, collaboration with highly specialized medical institutions is crucial. The expansion of trial sites nationwide is expected to improve patient accessibility and facilitate smoother enrollment processes. RIBOMIC plans to further expand the network to sixteen sites in total.

The company stated that there would be no impact on the fiscal year ending March 2027 due to this expansion. Further details on the trial design and safety aspects can be found in previous disclosures dated March 18, 2026, and July 01, 2026. Umedaptanib pegol, designated as RBM-007, is anticipated to offer a fundamental treatment approach by strongly inhibiting FGF2 function, addressing the underlying mechanism of achondroplasia. The drug has also been recognized as an orphan medicinal product by the Ministry of Health, Labour and Welfare. Achondroplasia affects approximately one in every 25,000 newborns, making it a rare disease requiring effective new treatments.